SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Jensen Huangs admission of an affair and Nvidias independent board investigation are drawing attention amid reports that the woman was a suspected Chinese intelligence asset. Traders are split over possible governance and national-security fallout, including whether Huang could leave the CEO role, while others view it as personal news that does not change Nvidias business; any compromise of company secrets remains unconfirmed.

XRP (XRP) is a cryptocurrency . XRP has a current supply of 99,985,583,260 with 63,516,606,953 in circulation. The last known price of XRP is 1.16094256 USD and is down -1.49 over the last 24 hours. It is currently trading on 1894 active market(s) with $1,342,393,155.38 traded over the last 24 hours. More information can be found at https://xrpl.org/.

Ripple

XRPs sharp slide alongside broader crypto weakness is driving discussion, with bearish traders warning of further losses while holders describe the pullback as a buying opportunity. Some traders also blame election-related uncertainty and fears that crypto legislation could stall, though those explanations remain speculative.

Bitcoin (BTC) is a cryptocurrency launched in 2010. Users are able to generate BTC through the process of mining. Bitcoin has a current supply of 20,109,371. The last known price of Bitcoin is 75,663.53857906 USD and is down -0.17 over the last 24 hours. It is currently trading on 12776 active market(s) with $9,277,191,640.33 traded over the last 24 hours. More information can be found at https://bitcoin.org/.

Bitcoin

Bitcoins sharp selloff and volatile trading have dominated discussion, with traders focused on whether key support will hold and pointing to leveraged liquidations as a possible driver. The community is split between calling the drop a buying opportunity or bear trap and expecting further downside; explanations tying it to geopolitical or Nvidia-related headlines remain speculative.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

Reports of Nvidia CEO Jensen Huangs affair with a woman suspected of Chinese intelligence ties, and the resulting board probe, dominate discussion as traders debate potential governance and national-security risks and whether Nvidia weakness could weigh on the AI trade and broader market. Reactions are split between those bracing for further tech-led volatility and those dismissing the story as personal or already priced in.

Ethereum (ETH) is a cryptocurrency . Ethereum has a current supply of 122,197,894.00927157. The last known price of Ethereum is 2,232.83367397 USD and is down -0.19 over the last 24 hours. It is currently trading on 14283 active market(s) with $3,862,469,414.23 traded over the last 24 hours. More information can be found at https://www.ethereum.org/.

Ethereum

Ethereum is drawing attention amid a sharp crypto-wide selloff, with traders pointing to leveraged-long liquidations and weak broader risk sentiment; proposed macro and political causes remain speculation, with no clear ETH-specific catalyst established. Bears see further downside, while bulls are buying the dip and arguing the decline may be nearing a floor.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ discussion centers on volatility in megacap tech and AI, with traders weighing fears that Democratic gains could constrain data-center expansion and AI spending alongside reports about Nvidia CEO Jensen Huangs relationship with a woman suspected of Chinese intelligence ties. Bears see the AI trade unraveling, while dip buyers argue the headlines are overblown and point to sharp rebounds.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

GLD is drawing attention amid a sharp reversal in gold: traders linked an earlier bounce to post-election uncertainty and a softer dollar and yields, while stronger jobs data, a firmer dollar and renewed Fed-hike expectations have pressured prices. The community is split between dip buyers expecting gold to regain its safe-haven role and bears who see more downside and question that hedge status.

Stellar (XLM) is a cryptocurrency launched in 2014. Stellar has a current supply of 50,001,786,837.39707 with 35,372,680,256.2826 in circulation. The last known price of Stellar is 0.15097866 USD and is down -1.62 over the last 24 hours. It is currently trading on 848 active market(s) with $82,748,701.06 traded over the last 24 hours. More information can be found at https://www.stellar.org.

Stellar Lumens

XLMs persistent slide and repeated selling pressure are driving the conversation, with traders watching support levels and warning of further downside. Others view the pullback as a buying opportunity, while some bullish holders point to Stellars tokenization and institutional-partnership story but question whether adoption will translate into demand for the token.

Algorand (ALGO) is a cryptocurrency launched in 2019. Algorand has a current supply of 10,000,000,000 with 9,078,398,959.154897 in circulation. The last known price of Algorand is 0.09511009 USD and is down -1.88 over the last 24 hours. It is currently trading on 586 active market(s) with $50,888,027.03 traded over the last 24 hours. More information can be found at http://algorand.foundation.

Algorand

Algorands steep decline is prompting debate over whether recent weakness marks capitulation and a potential double-bottom bounce or whether the downtrend will continue. Some traders are accumulating the dip, while bears point to weak momentum and broader crypto-market vulnerability.

Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: United States, Europe, and International Markets. The United States segment focuses on therapeutic area of central nervous system (CNS) portfolio, and is involved in the distribution business of generic, biosimilar and medicines, and over-the-counter (OTC) pharmaceutical products from the firm and third-party manufacturers to independent retail pharmacies, pharmacy retail chains, hospitals, and physician offices in the United States. The Europe segment offers OTC portfolio including SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brands in European Union, the United Kingdom, and certain other European countries. The International Markets segment provides its products to countries such as Canada, Israel, Russia, Latin America, and Japan. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Teva- Pharmaceutical Industries Ltd.

Teva- Pharmaceutical Industries Ltd. - ADR

Tevas quarterly results beat expectations and the company raised its outlook, with traders highlighting growth in innovative brands as a counterweight to pressure in generics. The reaction is broadly bullish, while traders are also watching the pending FDA decision on at-home Igalmi.

statis crypto Watchlist

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Federal Peptide Policy Shift Could Ignite a New Wave Of Growth Across The $164 Billion Peptide Market

New HHS Direction Creates Potential Opportunities For Peptide Manufacturers, Biotech Companies, And Healthcare Innovators    New York, NY –November 5, 2026 – The federal government’s October 30, 2026, decision could be a big deal for the peptide industry. HHS has signaled that it does not intend to pursue enforcement action against qualifying state-licensed pharmacies, federal […]
The post Federal Peptide Policy Shift Could Ignite a New Wave Of Growth Across The $164 Billion Peptide Market appeared first on Financial News Media.

Can NVO's Semaglutide Push Create Growth Beyond Cardiometabolic Care?

Novo's semaglutide expansion into liver disease and other obesity-related conditions can unlock growth, but competition and clinical risks loom.

VKTX Stock On Track To Beat LLY, NVO This Month After Obesity Drug Data — Can Viking Win Over Wegovy And Zepbound Users?

Equity

Obesity specialist Lou Aronne said switching from a GLP-1 drug to a dual GLP-1/GIP drug could mean greater weight loss.

VKTX, GPCR, ALT Stocks Rise: Novo Nordisk Signals Bigger M&A As It Chases Over 5 ‘Multi-Blockbusters’

Novo targets over $23 billion in risk-adjusted pipeline sales by 2035, excluding any contribution from future acquisitions.

Why Is Altimmune (ALT) Up 14.2% Since Last Earnings Report?

Altimmune (ALT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Is Altimmune Worth Buying as Cash Rises but Execution Risks Linger?

ALT's stronger cash position supports pemvidutide's MASH, AUD and ALD programs, but long timelines, funding needs and competition remain risks.

Altimmune's Phase III MASH Study Puts 2029 Data in Investor Focus

ALT has moved pemvidutide into Phase III MASH testing, with supportive mid-stage data, regulatory backing and a 2029 readout ahead.

Kodiak's Q2 Loss Wider Than Expected, Pipeline Development in Focus

KOD's Zenkuda advances toward regulatory submission as its pipeline gains momentum. Key clinical data is expected later in 2026.

ALT's Q2 Loss Narrower Than Expected, Pemvidutide's Studies in Focus

Altimmune posts a narrower Q2 loss. Its $519M in cash supports operations into 2029, while pemvidutide advances across liver and AUD studies.



BLTE Stock Rises as FDA Grants Priority Review to Tinlarebant NDA

Belite Bio's tinlarebant wins FDA priority review for Stargardt Disease, with a decision expected in February 2027 after positive phase III data.

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. Its lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Altimmune Inc

Bullish Sentiment

<ul class="summary-bullets"><li>VK2735 patients kept up to 97% of lost weight with shots every other week and up to 90% with monthly shots.</li><li>Aronne called stopping treatment the “biggest threat” to keeping weight off and said fewer shots could help.</li><li>Average analyst targets imply 131% upside for VKTX, versus 13% for LLY and 19% for NVO.</li></ul>A sharp rally in Viking Therapeutics (VKTX) has put its obesity drug VK2735 back in the spotlight, with the stock pulling ahead of Eli Lilly (LLY) and Novo Nordisk (NVO) as investors weigh whether Viking could one day draw patients away from Wegovy and Zepbound.<a href="https://stocktwits.com/symbol/VKTX">VKTX stock</a> jumped 36% on Tuesday, logging its biggest one-day gain in over 2 years, after Viking reported that patients who lost weight on weekly VK2735 injections kept most of it off when they moved to less frequent shots. Retail sentiment also hit a record high, adding to a rally that has made Viking a standout among obesity-drug stocks.VKTX has gained 25% over the past month, compared with a 1% rise for&nbsp;<a href="https://stocktwits.com/symbol/LLY">LLY</a> and a 13% decline for&nbsp;<a href="https://stocktwits.com/symbol/NVO">NVO</a>. Viking has also outpaced smaller obesity-drug developers&nbsp;<a href="https://stocktwits.com/symbol/ALT">Altimmune (ALT)</a>, up 10%, and&nbsp;<a href="https://stocktwits.com/symbol/GPCR">Structure Therapeutics (GPCR)</a>, down 20%.&nbsp;<img src="https://news.stocktwits-cdn.com/vktx_monthly_1622258c16.png" alt="vktx monthly.png"><h2 class="st-heading-2">Could Viking Win Over Rival Drug Users?</h2>During Tuesday’s study-results call, an analyst asked how VK2735 might perform in patients switching from approved injectables such as Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. Obesity specialist Lou Aronne said that the outcome could depend on the treatment a patient leaves.“Going from a triagonist to a dual agonist, you might expect some weight gain. Going from a mono-agonist to a dual agonist, you would expect greater weight loss,” Aronne said. For a switch between two dual agonists, he expects the magnitude of weight loss to be similar.&nbsp; Wegovy’s Semaglutide acts on GLP-1, while Zepbound’s Tirzepatide and Viking’s VK2735 act on both GLP-1 and GIP.&nbsp;&nbsp;However, Viking tested whether patients could maintain weight loss while taking fewer injections. In a study of about 180 adults with obesity, those receiving weekly VK2735 lost 16% to 19% of their body weight over 21 weeks. During the next 12 weeks, patients moved to every-other-week shots retained up to 97% of that loss, and those moved to monthly shots retained up to 90%. Patients switched to placebo retained 61%.&nbsp;An exploratory group that stayed on weekly VK2735 reached a mean weight loss of 21.7% at week 33, with no plateau observed. Gastrointestinal side effects during the less frequent maintenance schedules were similar to placebo.For Aronne, the opportunity is in helping patients stay on treatment after they reach their weight-loss goals. “If you look at the biggest threat to weight loss maintenance with the current drugs, it's that people stop taking them after a period of time,” he said. “If they could take them less frequently, I firmly believe that they would do a better job of it.”Viking hopes to examine both every-other-week and monthly dosing in extensions of its Phase 3 injectable trials. CEO Brian Lian said that the company has asked the FDA questions about dose selection and frequency and has not settled on the regimens.<h2 class="st-heading-2">VKTX’s Upside Forecast Dwarfs LLY And NVO&nbsp;</h2>Analysts also see more upside in Viking than in the established obesity-drug makers. VKTX’s average 12-month price target of $94.45 implies a 131% upside from current levels. Of the 20 analysts covering the stock, 5 rate it ‘Strong Buy,’ 13 rate it ‘Buy,’ and 2 rate it ‘Hold.’ None rate it ‘Sell’ or ‘Strong Sell.’Lilly’s average target of $1,325.39 implies a 13% upside from its last close. Among its 30 covering analysts, 6 rate it ‘Strong Buy,’ 19 ‘Buy,’ 3 ‘Hold,’ 1 ‘Sell’ and 1 ‘Strong Sell.’ Meanwhile, Novo’s implied upside stands at 19%, though its ratings are more cautious. Of 25 analysts, 5 rate it ‘Buy,’ 16 ‘Hold,’ 3 ‘Sell’ and 1 ‘Strong Sell.’ None rate it ‘Strong Buy.’Over the past year, VKTX and LLY each gained about 56%, while NVO fell 33%. Viking also outpaced the&nbsp;<a href="https://stocktwits.com/symbol/XLV">Health Care Select Sector SPDR Fund (XLV)</a>, up 26%, and the&nbsp;<a href="https://stocktwits.com/symbol/IBB">iShares Biotechnology ETF (IBB)</a>, up 47%, but trailed the&nbsp;<a href="https://stocktwits.com/symbol/XBI">SPDR S&amp;P Biotech ETF (XBI)</a>, which climbed 67%.<img src="https://news.stocktwits-cdn.com/vktx_1_year_28494b0880.png" alt="vktx 1-year.png"><h2 class="st-heading-2">Obesity Giants Building Their Next Line Of Defense&nbsp;</h2>Viking’s results come after a difficult start to the week for Novo. On Monday, the Wegovy maker presented Phase 3 data for its investigational drug CagriSema and outlined longer-term growth plans at its capital markets day. But investors remained concerned about competition and the future of its portfolio as key Semaglutide exclusivity approaches its end in the early 2030s.Novo CEO Mike Doustdar said on Tuesday that the company was interested in deals where an outside developer had produced a better drug that could fill a gap in its pipeline. Novo’s partnering strategy includes acquiring small and midsize biotech companies or their assets.&nbsp;Lilly has also been an active acquirer this year, expanding into areas beyond obesity through deals including Merida Biosciences and AtaiBeckley. Meanwhile, its existing weight-loss franchise continues to grow: second-quarter Zepbound sales hit about $4.9 billion, while Mounjaro, its diabetes drug containing the same active ingredient, generated about $9.9 billion.Viking is still building the evidence it would need to challenge the franchises. Its two injectable Phase 3 trials are fully enrolled, with results expected in 2027, and it is preparing Phase 3 studies of an oral VK2735 formulation.<h2 class="st-heading-2">How Do Retail Traders Feel About VKTX, NVO And LLY?</h2>Retail attention has picked up across all three stocks, though sentiment has moved in different directions.&nbsp;On Stocktwits, VKTX sentiment climbed to a record 95 out of 100, rising to 'extremely bullish' from 'bullish' a month ago, as message volume surged 352%&nbsp;over the same period. Followers are up 6% over the past year.Novo saw an even sharper&nbsp;shift,&nbsp;with sentiment&nbsp;swinging to ‘extremely bullish’ from ‘bearish,’ alongside a 210% jump in monthly message volume&nbsp;and a 36% rise in followers over the past year. Lilly’s sentiment improved to ‘neutral’ from ‘bearish,’ with message volume up 58% over the past month and followers up 17% over the past year.One user&nbsp;<a href="https://stocktwits.com/zackopaw/message/664831698">pointed</a> to Viking’s valuation alongside Zepbound and Mounjaro sales, saying, “Current mcap is 3.5 bn $. Do ur math.” Another&nbsp;<a href="https://stocktwits.com/biolover/message/664789310">argued</a> that Viking’s dosing options could appeal more than the Wegovy pill. However, a skeptical user&nbsp;<a href="https://stocktwits.com/dirtybug/message/664827065">cautioned</a> that people already doing well on Ozempic or Zepbound might be less likely to join VK2735 trials, making comparisons difficult.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/fisv-stock-climbs-overnight-after-7-day-red-streak-canada-s-winnipeg-blue-bombers-selects-clover-for-game-day-commerce/cZMEXL4RB7k">FISV Stock Climbs Overnight After 7-Day Red Streak: Canada’s Winnipeg Blue Bombers Selects Clover For Game-Day Commerce&nbsp;</a>

In this photo illustration, the Viking Therapeutics logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Structure Therapeutics Inc - ADR

iShares Biotechnology ETF

Lilly(Eli) & Co

Novo Nordisk A/S

Viking Therapeutics Inc

SPDR S&P Biotech ETF

Health Care Select Sector SPDR Fund

Up more than 1% 

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$2.08
Prev Close	$1.97
Open	$1.97
Dividend Yield	0.00%
50-Day Moving Average	$2.71
Beta	1.54
Avg. Volume	3.79M
PE Ratio	-2.64

52-Week High	$6.44
52-Week Low	$1.91
Market Capitalization	$404.6M
EPS (Annual)	-$0.9999
Price to Book	0.85
Revenue Per Employee	$719.30

Feed

News

Sentiment

Earnings

Fundamentals

Info

ALT Fundamentals